Page 16 - Read Online

Page 10 of 10 Quenelle et al. J Unexplored Med Data 2018;3:7 I http://dx.doi.org/10.20517/2572-8180.2018.02

23. Ma BB, Goh BC, Lim WT, Lo KW, Hui EP, Riess JW, Agulnik M, Chang AY, Kish JA, Lim DW, Adkins DR, Cullen KJ, Gitlitz
BJ, Foster NR, Pettinger AM, McKinzie S, To KF, Costello B, Streicher H, Chan AT. Abstract CT076: multicenter phase II study of
nivolumab in previously treated patients with recurrent and metastatic non-keratinizing nasopharyngeal carcinoma - mayo clinic phase 2
consortium P2C-MN026, NCI9742, NCT02339558. Cancer Res 2018; doi: 10.1158/1538-7445.AM2017-CT076.
24. Cohen RB, Delord JP, Doi T, Piha-Paul SA, Liu SV, Gilbert J, Algazi AP, Damian S, Hong RL, Le Tourneau C, Day D, Varga A, Elez
E, Wallmark J, Saraf S, Thanigaimani P, Cheng J, Keam B. Pembrolizumab for the treatment of advanced salivary gland carcinoma:
findings of the phase 1b KEYNOTE-028 study. Am J Clin Oncol 2018; doi: 10.1097/COC.0000000000000429.
25. Diggs LP, Hsueh EC. Utility of PD-L1 immunohistochemistry assay for predicting PD-1/PD-L1 inhibitor response. Biomark Res
2017;5:12.
26. Rimm DL, Han G, Taube JM, Yi ES, Bridge JA, Flieder DB, Homer R, West WW, Wu H, Roden AC, Fujimoto J, Yu H, Anders R,
Kowalewski A, Rivard C, Rehman J, Batenchuk C, Burns V, Hirsch FR, Wistuba II. A prospective, multi-institutional, pathologist-based
assessment of 4 immunohistochemistry assays for PD-L1 expression in non-small cell lung cancer. JAMA Oncol 2017;3:1051-8.
27. Yearley JH, Gibson C, Yu N, Moon C, Murphy E, Juco J, Lunceford J, Cheng J, Chow LQM, Seiwert TY, Handa M, Tomassini JE,
McClanahan T. PD-L2 expression in human tumors: relevance to anti-PD-1 therapy in cancer. Clin Cancer Res 2017;23:3158-67.
28. Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, Chau I, Ernstoff MS, Gardner JM, Ginex P, Hallmeyer
S, Holter Chakrabarty J, Leighl NB, Mammen JS, McDermott DF, Naing A, Nastoupil LJ, Phillips T, Porter LD, Puzanov I, Reichner
CA, Santomasso BD, Seigel C, Spira A, Suarez-Almazor ME, Wang Y, Weber JS, Wolchok JD, Thompson JA; National Comprehensive
Cancer Network. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy:
American Society of Clinical Practice Guideline. J Clin Oncol 2018;36:1714-68.
29. Puzanov I, Diab A, Abdallah K, Bingham CO, III, Brogdon Dadu CR, Hamad L, Kim S, Lacouture ME, LeBoeuf NR, Lenihan
D, Onofrei C, Shannon V, Sharma R, Silk AW, Skondra D, Suarez-Almazor ME, Wang Y, Wiley K, Kaufman HL, Ernstoff MS,
corresponding author and on behalf of the Society for Immunotherapy of Cancer Toxicity Management Working Group. Managing
toxicities associated with immune checkpoint inhibitors: concensus recommendations from the Society for Immunotherapy of Cancer
(SITC) Toxicity Management Working Group. J Immunother Cancer 2017;5:95.
30. Minor DR, Chin K, Kashani-Sabet M. Infliximab in the treatment of anti-CTLA4 antibody (ipilumumab) induced immune-related
colitis. Cancer Biother Radiopharm 2009;24:321-5.
31. Menzies AM, Johnson DB, Ramanujam S, Atkinson VG, Wong ANM, Park JJ, McQuade JL, Shoushtari AN, Tsai KK, Eroglu Z, Klein O,
Hassel JC, Sosman JA, Guminski A, Sullivan RJ, Ribas A, Carlino MS, Davies MA, Sandhu SK, Long GV. Anti-PD-1 therapy in patients
with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Ann Oncol 2017;28:368-76.
32. Gutzmer R, Koop A, Meier F, Hassel JC, Terheyden P, Zimmer L, Heinzerling L, Ugurel S, Pföhler C, Gesierich A, Livingstone E,
Satzger I, Kähler KC; German Dermatooncology Group (DeCOG). Programmed cell death protein-1 (PD-1) inhibitor therapy in patients
with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity. Eur J Cancer 2017;75:24-32.
33. Abdel-Wahab N, Shah M, Lopez-Olivo MA, Suarez-Almazor ME. Use of immune checkpoint inhibitors in the treatment of patients
with cancer and preexisting autoimmune disease: a systematic review. Ann Intern Med 2018;168:121-30.
34. Kittai AS, Oldham H, Cetnar J, Taylor M. Immune checkpoint inhibitors in organ transplant patients. J Immunother 2017;40:277-81.
35. Chae YK, Galvez C, Anker JF, Iams WT, Bhave M. Cancer immunotherapy in a neglected population: the current use and future of
T-cell-mediated checkpoint inhibitors in organ transplant patients. Cancer Treat Rev 2018;63:116-21.